Inovio licenses preclinical immunotherapy vaccines to Roche

Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine

Read the full 155 word article

How to gain access

Continue reading with a
two-week free trial.